What is the address of SATER MED?

The registered office of SATER MED is located at Gentsesteenweg 204, 1080 Sint-Jans-Molenbeek.

Is SATER MED still active?

Yes. According to the CBE (19 September 2026) SATER MED is active, legal situation “Normale toestand”, started on 1 December 2011.

Is SATER MED registered on Peppol?

No, SATER MED is currently not registered on the Peppol network.

What is the enterprise number of SATER MED?

The enterprise number of SATER MED is BE0841456588.

When was SATER MED founded?

SATER MED was founded on 1 December 2011.

Who are the directors of SATER MED?

According to the 2025 annual accounts, the directors of SATER MED are: Ali Abdul-Sater.

Is SATER MED a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 December 2011; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did SATER MED make in 2025?

SATER MED recorded a loss after taxes of € 54,296 in financial year 2025.

What is the revenue of SATER MED?

As a small company, SATER MED is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -51,828.

SATER MED (Private Limited) - Sint-Jans-Molenbeek

Dossier SATER MED, printed on 19 September 2026 from databakkes.be/en/0841456588/sater-med. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

SATER MED from Sint-Jans-Molenbeek, company number BE0841456588, closed financial year 2025 with a result of € -54,296 after tax. For that financial year SATER MED recorded a gross margin of € -51,828 and equity of € 119,622. Compared with financial year 2024, the result moved from € 10,991 to € -54,296. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 30, 2025.

What it is worth Healthy

€ 119,622

▼ 31% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -54,296

▼ still € 10,991 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 104,223

▼ 36% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 107,222.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

€ 7,443

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 2,240

▲ € 2,063 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,000

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 40,390 Gross margin 2022: € 40,390 First fiscal year in the series	€ 31,873 Gross margin 2023: € 31,873 ▼ 21% vs 2022 (€ 40,390) Unfavourable step	€ 19,486 Gross margin 2024: € 19,486 ▼ 39% vs 2023 (€ 31,873) Unfavourable step	€ -51,828 Gross margin 2025: € -51,828 ▼ € 71,314 vs 2024 (€ 19,486) Unfavourable step	▼ € 71,314
Profit after taxes	€ 23,877 Profit after taxes 2022: € 23,877 First fiscal year in the series	€ 21,070 Profit after taxes 2023: € 21,070 ▼ 12% vs 2022 (€ 23,877) Unfavourable step	€ 10,991 Profit after taxes 2024: € 10,991 ▼ 48% vs 2023 (€ 21,070) Unfavourable step	€ -54,296 Profit after taxes 2025: € -54,296 ▼ € 65,287 vs 2024 (€ 10,991) Unfavourable step	▼ € 65,287
Equity	€ 200,857 Equity 2022: € 200,857 First fiscal year in the series	€ 193,927 Equity 2023: € 193,927 ▼ 3% vs 2022 (€ 200,857) Unfavourable step	€ 173,918 Equity 2024: € 173,918 ▼ 10% vs 2023 (€ 193,927) Unfavourable step	€ 119,622 Equity 2025: € 119,622 ▼ 31% vs 2024 (€ 173,918) Unfavourable step	▼ 31%
Total debts	€ 12,064 Total debts 2022: € 12,064 First fiscal year in the series	€ 11,732 Total debts 2023: € 11,732 ▼ 3% vs 2022 (€ 12,064) Favourable step	€ 10,610 Total debts 2024: € 10,610 ▼ 10% vs 2023 (€ 11,732) Favourable step	€ 12,683 Total debts 2025: € 12,683 ▲ 20% vs 2024 (€ 10,610) Unfavourable step	▲ 20%
Cash	€ 149,904 Cash 2022: € 149,904 First fiscal year in the series	€ 164,328 Cash 2023: € 164,328 ▲ 10% vs 2022 (€ 149,904) Favourable step	€ 163,526 Cash 2024: € 163,526 Unchanged (€ 164,328) Unfavourable step	€ 104,223 Cash 2025: € 104,223 ▼ 36% vs 2024 (€ 163,526) Unfavourable step	▼ 36%
Retained profit	€ 188,457 Retained profit 2022: € 188,457 First fiscal year in the series	€ 181,527 Retained profit 2023: € 181,527 ▼ 4% vs 2022 (€ 188,457) Unfavourable step	€ 161,518 Retained profit 2024: € 161,518 ▼ 11% vs 2023 (€ 181,527) Unfavourable step	€ 107,222 Retained profit 2025: € 107,222 ▼ 34% vs 2024 (€ 161,518) Unfavourable step	▼ 34%
Dividend	€ 31,818 Dividend 2022: € 31,818 First fiscal year in the series	€ 28,000 Dividend 2023: € 28,000 ▼ 12% vs 2022 (€ 31,818) Unchanged	€ 31,000 Dividend 2024: € 31,000 ▲ 11% vs 2023 (€ 28,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 31,000) Unchanged	▼ 100%
Bank debt	€ 7,500 Bank debt 2022: € 7,500 First fiscal year in the series	€ 7,500 Bank debt 2023: € 7,500 Unchanged (€ 7,500) Unchanged	€ 7,433 Bank debt 2024: € 7,433 ▼ 1% vs 2023 (€ 7,500) Favourable step	€ 7,443 Bank debt 2025: € 7,443 Unchanged (€ 7,433) Unfavourable step
Balance sheet total	€ 212,921 Balance sheet total 2022: € 212,921 First fiscal year in the series	€ 205,660 Balance sheet total 2023: € 205,660 ▼ 3% vs 2022 (€ 212,921) Unchanged	€ 184,528 Balance sheet total 2024: € 184,528 ▼ 10% vs 2023 (€ 205,660) Unchanged	€ 132,305 Balance sheet total 2025: € 132,305 ▼ 28% vs 2024 (€ 184,528) Unchanged	▼ 28%

Key figures of SATER MED, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to SATER MED?

What happened at SATER MED in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 30, 2025 New annual accounts for financial year 2025: loss of € 54,296 (▼ € 65,287 vs 2024). Source: NBB ↗
Dec 1, 2011 Start of the company according to the CBE. KBO
Nov 25, 2011 New establishment in Sint-Jans-Molenbeek. KBO

In short

From € 23,877 profit in 2022 to € 54,296 loss in 2025.

Paid € 24,204 in corporate taxes since 2022.

Best year ever: 2022, with € 23,877 profit.

Paid out € 90,818 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at SATER MED? We notify you, reason included.

Follow SATER MED

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Ali Abdul-Sater

SATER MED

Behind SATER MED is Ali Abdul-Sater.

See the full network in the app

Directors

According to the 2025 annual accounts

Ali Abdul-Sater

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Gentsesteenweg 204

1080 Sint-Jans-Molenbeek

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0841.456.588
VAT number: BE 0841.456.588
Registered office: Gentsesteenweg 204, 1080 Sint-Jans-Molenbeek
Names & denominations: SATER MED
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 1 December 2011
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗